LXEO · Lexeo Therapeutics Inc.
AI read · Good for LXEO
The AI's read
These findings give Lexeo early evidence that LX2020 may reduce heart rhythm problems. Six of 7 high-dose patients improved, and the FDA is open to a heart rhythm measure for a possible faster approval path. The results came from a small group, and the planned larger study is not expected to start until late 2027. One patient had a serious heart rhythm event, and some patients had liver test rises that doctors managed.